/

GMAB.CO

Genmab A/SOpen

2,443.00−27.00 −1.09%DKK

Copenhagen · as of Oct 14, 04:55 ET

Open

2,419.00

Prev close

2,470.00

Day range

2,404.002,448.00

52-week range

1,512.002,603.00

Volume

15.46K0.13×

Mkt cap

150.22B

P/E ttm

29.92

Fwd P/E

22.14

EPS ttm

81.64

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−6.15%

Price Chart

Yahoo Finance · delayed

GMAB.COOct 14, 2026O 2,419.00H 2,448.00L 2,404.00C 2,443.00−27.00 (−1.09%)Vol 15.46K

SMA 502,204.98
SMA 2001,922.73

1Y change +17.62% since Oct 13, 2025 close537 bars loadedTimes in Europe/CopenhagenDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

GMAB.CO Genmab A/S · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.77%
1 month: +15.45%
3 months: +28.85%
6 months: +32.84%
Year to date: +20.52%
1 year: +17.17%

Valuation & ownership

Market cap: 150.22B
Enterprise value: 151.23B
P/E (ttm): 29.92
Forward P/E: 22.14
PEG ratio: 4.63
Price / book: 3.65
Price / sales (ttm): 36.36
EV / EBITDA: 109.82
EPS (ttm): 81.64
EPS (forward): 110.36
Beta (5y monthly): 0.65
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 61.49M
Float: 55.30M
Short % of float: —
Short ratio (days): —
Held by insiders: 1.12%
Held by institutions: 47.35%
Avg volume (3m): 120.08K
50-day average: 2,182.12
200-day average: 1,909.99
52-week change: +17.17%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 61.4
vs 50-day SMA: +10.79%
vs 200-day SMA: +27.06%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.14%
Realised vol (20d, ann.): 37.1%
From 52-week high: −6.15%
From 52-week low: +61.57%

ANR

Analyst Consensus

15 analysts

Consensus

Buy

1.59 on a 1 (strong buy) – 5 (sell) scale

Mean target

2,609.12

+6.80% implied

Low 1,400.00Median 2,850.00High 3,310.00

Recommendation trend

Now14 / 2 / 1
1m ago

DES

About Genmab A/S

Yahoo Finance profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Sector: Healthcare
Industry: Biotechnology
Employees: 3,119
Headquarters: Copenhagen, Denmark
Website: genmab.com

SEAS

Seasonality · GMAB.CO

2007–2026 · monthly returns

Strongest month Jul +8.71%Weakest month Jun −2.03%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-0.2	-8.6	-7.3	-1.3	0.8	5.3	3.5	14.2	10.4	4.3			+20.5%
2025	-4.6	12.9	-16.7	3.7	-0.8	-4.7	9.3	10.5	21.4	-4.6	10.9	-0.6	+35.8%
2024	-10.9	0.5	8.0	-6.1	-1.0	-9.9	12.0	-4.2	-13.5	-5.3	-0.6	-2.2	−30.7%
2023	-9.1	-0.9	-2.2	7.4	-2.0	-5.3	8.0	-5.3	-5.0	-20.7	8.6	-0.3	−26.7%
2022	-15.2	-0.0	10.5	1.6	-15.6	8.7	13.0	1.7	-6.8	18.0	12.6	-10.0	+11.8%
2021	-0.5	-15.5	0.8	8.8	8.5	4.2	10.5	5.2	-5.8	2.7	-12.0	3.6	+6.8%
2020	5.1	-2.3	-9.5	18.9	25.8	7.8	-2.7	9.1	-2.4	-7.4	12.4	2.9	+66.3%
2019	-11.3	19.7	1.9	-4.3	3.8	5.2	3.7	10.6	0.4	5.0	8.2	-6.2	+38.8%
2018	6.7	13.6	4.1	-3.5	-23.5	2.8	10.9	1.7	-9.1	-10.7	11.1	6.4	+3.7%
2017	13.2	4.7	-3.4	1.1	4.1	-1.7	2.9	2.0	-4.7	-7.2	-4.7	-16.3	−12.3%
2016	-6.4	-1.8	7.6	6.1	25.4	0.2	-0.3	-11.6	6.0	-1.1	8.8	-3.5	+27.8%
2015	22.9	11.3	6.1	-1.7	16.1	-2.4	9.9	-6.6	2.3	9.4	33.4	2.8	+154.6%
2014	3.6	11.2	-9.8	-9.3	10.3	5.4	-3.9	1.3	10.5	3.6	14.2	21.8	+70.0%
2013	26.0	5.0	30.7	9.7	39.6	-15.5	-6.9	3.0	35.4	5.5	-4.6	-6.8	+172.5%
2012	18.8	-3.5	7.2	-3.0	-6.2	39.2	6.2	26.4	-7.1	9.9	-4.9	2.0	+106.9%
2011	-3.5	-9.7	-1.9	-2.9	-12.3	-16.1	0.6	-7.6	-12.8	-2.8	-13.3	37.7	−42.6%
2010	19.5	-6.3	-24.4	-11.0	-22.3	-9.3	40.4	-8.8	10.7	15.4	-9.0	1.2	−20.1%
2009	20.2	-7.9	-5.7	3.2	-10.9	-6.0	14.1	-28.7	-11.9	1.3	-42.1	6.5	−59.6%
2008	-3.4	-2.8	-17.2	8.1	-1.0	-29.6	42.0	27.8	-8.7	-12.3	-1.1	-21.9	−34.3%
2007	-4.6	-7.9	1.8	13.2	3.5	-11.3	-4.1	-5.0	0.9	7.5	-9.6	-2.2	−18.7%

GMAB.CO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

GMAB.CO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Genmab A/S

Seasonality · GMAB.CO

Insider Activity · GMAB.CO

Congress Trades · GMAB.CO

Investors Holding GMAB.CO

Investors Holding GMAB.CO

Congress Trades · GMAB.CO

Insider Activity · GMAB.CO

Seasonality · GMAB.CO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Genmab A/S

Financial Snapshot

Earnings & Dividends

News